Life quality in hypertensive patients during therapy with rilmenidine versus atenolol
https://doi.org/10.18705/1607-419X-2004-10-4-211-214
Abstract
The paper evaluates the impact of 26-week therapy with rilmenidine in a dose of 1-2 mg daily and with atenolol in a dose of 50 100 mg daily on life quality parameters determined by the SF-Зб scale in 51 patients with essential hypertension during an open randomized controlled study in parallel groups. Most life quality parameters were found to improve during monotherapy with both drugs. Whereas there was a deterioration in some life quality subspheres (social and emotional) during atenolol therapy, which was not observed in a group of patients receiving rilmenidine where there were minimal adverse reactions that did not require discontinuance of therapy or correction the dose.
About the Authors
Yu. R. Kasherininov
Almazov Research Cardiology Institute
Russian Federation
Russian Federation
A. A. Shavarov
Almazov Research Cardiology Institute
Russian Federation
Russian Federation
S. V. Villevalde
Almazov Research Cardiology Institute
Russian Federation
Russian Federation
A. O. Konradi
Almazov Research Cardiology Institute
Russian Federation
Russian Federation
Ye. V. Shlyakhto
Almazov Research Cardiology Institute
Russian Federation
Russian Federation
References
1. l. 2003 Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
2. ACC/AHA 2002. (Guidelines Update for the Management of Patients With Chronic Stable Angina. J Am Coll Cardiol 2003; 1.
3. Ипатов А.В., Лехан B.Н., Панина C.C., Гондуленко Н.А. Качество жизни у больных и инвалидов вследствие гипертонической болезни. Кардиология СНГ. 2003; 1 (1): 109.
4. Luccioni R. Pharmacoepidemiological Assessment of Hyperium (Rilmenidine) in 18235 Hypertensive Patients. Presse Med 1995; 24: 1857-64.
5. Reid J.L. Update on Rilmenidine: Clinical Benefits. Am J Hypertens 2001: 14: 322-4.
6. Рекомендации по профилактике, диагностике и течению артериальной гипертензии. Артериальн. Гипертензия 2000; 7 (1): Приложение.
7. Кашерининов Ю.Р., Шаварова Е.К., Шаваров А.А. и др. Динамика показателей углеводного и липидного обмена у больных гипертонической болезнью на фоне терапии рилменидином в сравнении с aтeнололом. Артериальн. Гипертензия. 2004; 10: 28-32.
8. Мамонтов О.В., Кашерининов Ю.Р., Шаваров А.А., Конради А.О. Влняние терапии рилменидином в сравнении с атенололом на состояние барорефлекторной регуляции кровообращения у больных гипертонической болезнью. Связь с суточным профилем артериального давления и выраженностью антигипертензивного эффекта. Артериальн. гипертензия. 2004: 10: 126-8.
9. Ware J.E., Shubouene C.D. The Mos 36-item Short-Form Health Survey (SF-36). I Conceptual framework and item selection. Medical Care 1992: 30 (6): 473-83.
10. McHomey C.A., Ware J.E., Raczek A.E. The Mos 36-item Short-Form Health Survey (SF-36). II Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993; 31 (3): 247-63.
11. Чирейкин Л.В., Варшавский С.Ю., Бурова H.Н., Булыгипа Н.Е. Оценка качества жизни у больных с нарушением функции синусового угла. Вестн. аритмол. 1998, 10. 39-43.
12. Kusek J.W., Lee J.Y., Smith D.E. et el Effect of blood pressure control and antihypertensive drug regimen on quality of life the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996 Aug; 17 (4 Suppl.): 40S-46S.
13. Groog S.H., Elias M.F., Colton T. el al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994 Apr, 7 (4 Pt 1): 329-39.
14. Yao X.Y., Fаn W.H., Chen J.Z. et al. Effects of atenolol and diltiazem-SR on quality of life in the hypertensive patients Zhejiang Da Xue Xue Bao Yi Хuе Ban. 2003 Jun: 32 (3): 231-4.
15. Cleophas T.J., vd Mey N., Meulen J., Niemeyer M.G. Quality of life before and during antihypertensive treatment: a comparative study of celiprolol and atenolol. Am J Ther 1997Apr: 4 (4): 117-22.
16. Fletcher A.E., Beevers D.G., Dollery C.T. et al. The effects of two centrally-acting and hypertensive drugs on the quality of life. Eur Clin Pharmacol 1991: 41 (5) 397-400.
17. Passeron J., Gulltet С. Treatment with rilmenidine 1 mg per day: time-lag to maximum response. A multicenter ambulatory study. Le Groupe Francais d'elude Multicentrique d'Hyperium Presse Med. 1992 Dec 12; 21 (43): 2089-93.
18. Staessen J.A., Fagard R., Thijs L. et al. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64.
Review
For citations:
Kasherininov Yu.R., Shavarov A.A., Villevalde S.V., Konradi A.O., Shlyakhto Ye.V. Life quality in hypertensive patients during therapy with rilmenidine versus atenolol. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2004;10(4):211-214. (In Russ.) https://doi.org/10.18705/1607-419X-2004-10-4-211-214
Views:
785
Email this article 